I thought the IMUC data set was the best because this trial had published results one could use the IMUC survival curve to determine the events in the control arm and the entry requirements for the IMUC were very similar to the NWBO trial.
The Stupp Trial would not be good because Stupp had 18% of patients that had biopsy only and did not have a Gross total or near total resection.
Also the fact that IMUC is valued at 2.5 million now has no relevance regarding the quality of their dataset.
The analysis of mine and others further reinforces my belief that we are looking at a positive trial for DCVax-L.
As an investor I think that this is a great opportunity to purchase shares of a company before the good news is released with associated potential share appreciation.
News 
Market Data 
Discover 
